It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.

Disclosed herein are compositions comprising a chimeric antigen receptor targeting phosphatidylserine on the surface of cancer cells and methods of using the compositions to treat a cancer in a subject.

Disclosed herein are compositions comprising a chimeric fusion protein targeting phosphatidylserine on the surface of hematological cancer cells and methods of using the compositions to treat a hematological cancer in a subject.

Provided are humanized anti-HLA-A2 antibodies. In certain aspects, the humanized anti-HLA-A2 antibodies are capable of constituting an antigen binding domain of a chimeric antigen receptor (CAR), where the CAR is capable of being expressed in a human cell such that the CAR specifically binds to HLA-A2. Also provided are CARs that include the humanized anti-HLA-A2 antibodies. Modified cells including the antibodies and CARs, as well as methods of using such modified cells are also provided.

Provided relates to a circular RNA comprising an internal ribosome entry site (IRES) element, a protein coding sequence and a poly A. Provided also relates to the precursor RNA, the vector and the method for producing the circular, and the use of the circular RNA.

Provided relates to a circular RNA comprising an internal ribosome entry site (IRES) element, a protein coding sequence and a poly A. Provided also relates to the precursor RNA, the vector and the method for producing the circular, and the use of the circular RNA.

The present invention relates to an engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a myelin basic protein (MBP) peptide or variant or fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule. The present invention further relates to methods for providing an engineered Treg and to methods and uses of said engineered Treg and vectors and kits of vectors encoding said Treg.

Provided is a method for producing regulatory T cells, comprising the step of culturing mammalian-derived peripheral T cells in a medium comprising TGF and IL-2 in the presence of CD3 stimulation and in the absence of CD28 stimulation. The medium may further comprise ascorbic acid. The method may further comprise the step of culturing the obtained cell culture in a medium comprising IL-2.

The present technology relates generally to compositions and methods for creating recombinant T cell receptor (TCR) libraries and methods of their therapeutic use. The compositions and methods of the present technology are useful for rapid isolation of antigen-specific TCR repertoires as personalized, targeted therapies for cancer and viral infection.

Provided herein are methods of transducing T cells using CD3-targeted viral vectors.